EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

NCT01257594 PHASE1 COMPLETED

The purpose of this study is to test the effectiveness of a drug called erlotinib in treating the tumor. This is a multi-center pilot study that explores efficacy and molecular effects of high dose weekly erlotinib for recurrent EGFR vIII mutant malignant gliomas, and correlate molecular profile of pre-treatment tissue with outcome.

Details

Lead sponsor	Andrew B Lassman, MD
Phase	PHASE1
Status	COMPLETED
Enrolment	22
Start date	Fri Jan 07 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Brain Cancer

Interventions

• erlotinib
• Cytoreductive Surgery

Countries

United States